Next-Generation Ctla-4 Targeting Molecules and Combination Therapy: Promising Strategies for Improving Cancer Immunotherapy

Authors

Nils-Petter Rudqvist
Manushak Avagyan
Dhan Chand

Publication Date

1-1-2023

Journal

OncoImmunology

Abstract

Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.

Keywords

Clinical trials, CTLA-4 blockade, immune checkpoint blockade, next generation immunotherapy, radiation therapy

Comments

PMID: 37937212